Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	4355	(paclitaxel or taxane or docetaxel or taxol or taxotere) and (analog or analogue or alternative) and design	US-PGPUB; USPAT	OR	ON	2004/10/15 09:07
L2	438	(paclitaxel or taxane or docetaxel or taxol or taxotere) and (synthetic adj2 (analog or analogue or alternative)) and design	US-PGPUB; USPAT	OR	ON	2004/10/15 09:27
L3	1	("6593374").PN.	US-PGPUB; USPAT	OR	OFF	2004/10/15 09:26
L4	132	(paclitaxel or taxane or docetaxel or taxol or taxotere) and (synthetic adj2 (derivative)) and design	US-PGPUB; USPAT	OR	ON	2004/10/15 09:31
L5	118	4 not 2	US-PGPUB; USPAT	OR	ON	2004/10/15 09:27
L6	551	(paclitaxel or taxane or docetaxel or taxol or taxotere) and drug adj design and computer	US-PGPUB; USPAT	OR	ON	2004/10/15 09:31
L10	6707	((703/1-11) or (702/19-29)).CCLS.	US-PGPUB; USPAT	OR	OFF	2004/10/15 09:33
L11	4	l6 and l10	US-PGPUB; USPAT	OR	OFF	2004/10/15 09:34
L12	45	l1 and l10	US-PGPUB; USPAT	OR	OFF	2004/10/15 09:34

```
=> d his

     (FILE 'HOME' ENTERED AT 08:22:33 ON 15 OCT 2004)

     INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, AQUALINE, ANABSTR, ANTE,
     AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS,
     BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB,
     CROPU, DISSABS, DDFB, DDFU, DGENE, ...' ENTERED AT 08:22:52 ON 15 OCT 2004
               SEA (PACLITAXEL OR TAXANE) AND (DESIGN OR MODEL OR MODELING) AN
               ---------
             479   FILE ADISCTI
              51   FILE ADISINSIGHT
              14   FILE ADISNEWS
               2   FILE AGRICOLA
               1   FILE ANABSTR
               3   FILE ANTE
               1   FILE AQUASCI
               7   FILE BIOBUSINESS
               4   FILE BIOCOMMERCE
              21   FILE BIOENG
             792   FILE BIOSIS
              11   FILE BIOTECHABS
              11   FILE BIOTECHDS
             115   FILE BIOTECHNO
              13   FILE CABA
             201   FILE CANCERLIT
             260   FILE CAPLUS
              13   FILE CEN
               2   FILE CONFSCI
              44   FILE DISSABS
              48   FILE DDFU
              18   FILE IMSDRUGNEWS
             105   FILE DRUGU
              38   FILE IMSRESEARCH
               3   FILE EMBAL
             452   FILE EMBASE
             109   FILE ESBIOBASE
              89   FILE FEDRIP
              36   FILE IFIPAT
              16   FILE JICST-EPLUS
              29   FILE LIFESCI
             319   FILE MEDLINE
               2   FILE NTIS
             199   FILE PASCAL
               7   FILE PHAR
               5   FILE PHARMAML
              35   FILE PHIN
             382   FILE PROMT
               8   FILE PROUSDDR
             222   FILE SCISEARCH
               1   FILE SYNTHLINE
             439   FILE TOXCENTER
            3451   FILE USPATFULL
             343   FILE USPAT2
              23   FILE WPIDS
              23   FILE WPINDEX
L1             QUE (PACLITAXEL OR TAXANE) AND (DESIGN OR MODEL OR MODELING) AN
               ---------
               SEA (PACLITAXEL OR TAXANE) AND (DESIGN OR (MOLECULAR (W) MODEL
               ---------
```

```
  473   FILE ADISCTI
    5   FILE ADISINSIGHT
    2   FILE ADISNEWS
    1   FILE ANABSTR
    1   FILE ANTE
    1   FILE AQUASCI
    4   FILE BIOBUSINESS
    4   FILE BIOCOMMERCE
    2   FILE BIOENG
  127   FILE BIOSIS
    3   FILE BIOTECHABS
    3   FILE BIOTECHDS
   33   FILE BIOTECHNO
    2   FILE CABA
   56   FILE CANCERLIT
   89   FILE CAPLUS
   12   FILE CEN
    1   FILE CONFSCI
   16   FILE DISSABS
   15   FILE DDFU
    3   FILE IMSDRUGNEWS
   27   FILE DRUGU
    1   FILE EMBAL
  155   FILE EMBASE
   31   FILE ESBIOBASE
   49   FILE FEDRIP
    6   FILE IFIPAT
    5   FILE JICST-EPLUS
    2   FILE LIFESCI
   90   FILE MEDLINE
   64   FILE PASCAL
   16   FILE PHIN
  224   FILE PROMT
   65   FILE SCISEARCH
    1   FILE SYNTHLINE
  160   FILE TOXCENTER
 2167   FILE USPATFULL
  180   FILE USPAT2
    7   FILE WPIDS
    7   FILE WPINDEX
L2          QUE (PACLITAXEL OR TAXANE) AND (DESIGN OR (MOLECULAR (W) MODEL
            ---------

     FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS' ENTERED AT 08:30:31 ON 15 OCT 2004
L3            461 S L2
L4            343 DUP REM L3 (118 DUPLICATES REMOVED)
L5            343 FOCUS L4 1-

=> log y
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     191.85     199.47

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)            SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                     -21.00     -21.00

STN INTERN
```

L5 ANSWER 38 OF 343 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on Full Text
STN
AN 2004:245361 BIOSIS
DN PREV200400240212
TI Synthesis, **modeling**, and anti-tubulin activity of a D-seco **paclitaxel** analogue.
AU Barboni, Luciano [Reprint Author]; Giarlo, Guido; Ricciutelli, Massimo; Ballini, Roberto; Georg, Gunda I.; VanderVelde, David G.; Himes, Richard H.; Wang, Minmin; Lakdawala, Ami; Snyder, James P.
CS Dipartimento di Scienze Chimiche, Universita di Camerino, via S. Agostino 1, 62032, Camerino (MC), Italy
georg@ku.edu
SO Organic Letters, (February 19 2004) Vol. 6, No. 4, pp. 461-464. print.
ISSN: 1523-7060 (ISSN print).
DT Article
LA English
ED Entered STN: 6 May 2004
Last Updated on STN: 6 May 2004
AB We have previously described a model of **paclitaxel**-microtubule binding that led to the prediction that analogues of **paclitaxel** lacking any D ring could stabilize microtubules as well as **paclitaxel** if the substituent present at C4 did not have unfavorable steric interactions with the binding pocket. We report the synthesis of a 4-methyl **paclitaxel** analogue, compound 1, which bears this prediction out. Compound 1 is as potent as **paclitaxel** at microtubule stabilization in vitro; however, it has only about one-four-hundredth the cytotoxicity of **paclitaxel**.

AN 2002397778 EMBASE
TI Overcoming multidrug resistance in **taxane** chemotherapy.
AU Geney R.; Ungureanu I.M.; Li D.; Ojima I.
CS Dr. I. Ojima, Department of Chemistry, State Univ. of NY at Stony Brook, Stony Brook, NY 11794-3400, United States. IOJIMA@notes.cc.sunysb.edu
SO Clinical Chemistry and Laboratory Medicine, (2002) 40/9 (918-925).
Refs: 41
ISSN: 1434-6621 CODEN: CCLMFW
CY Germany
DT Journal; General Review
FS 016 Cancer
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LA English
SL English
AB **Paclitaxel** (Taxol®) and docetaxel (Taxotere®) are currently two of the most important anticancer drugs in cancer chemotherapy. However, clinical treatment with these **taxane** agents often encounters undesirable side effects and multidrug resistance (MDR) caused by overexpression of P-glycoprotein (Pgp). Photoaffinity labeling of Pgp using photoreactive radiolabeled **paclitaxel** analogs along with molecular **modeling** has revealed a unique binding region for **paclitaxel** on the C-terminal half of Pgp. Highly efficient **taxane**-based MDR reversal agents (TRAs) have been developed. Extensive structure-activity relationship (SAR) studies have led to the development of new generation **taxanes** that possess 2-3 orders of magnitude higher potencies against human cancer cell lines expressing the MDR phenotype. One of these **taxanes**, SB-T-110131 (IDN5109, BAY59-8862), exhibits excellent activity against a variety of drug-sensitive and drug-resistant cancer cell lines as well as human tumor xenografts in mice. This **taxane** is orally active with excellent bioavailability, and is currently undergoing phase II human clinical trials, Novel **taxane**-antibody immunoconjugates have shown very promising results for tumor-specific delivery and release of an extremely cytotoxic **taxane**, wherein epidermal growth factor receptor is used as the specific antigen on the tumor surface of human squamous cancer xenograft in SCID mice.

TI Medicinal chemistry and chemical biology of new generation **taxane** antitumor agents

AU Ojima, Iwao; Geney, Raphael; Ungureanu, Ioana Maria; Li, Dansu

CS Chemistry Department, State University of New York at Stony Brook, Stony Brook, NY, 11794-3400, USA

SO IUBMB Life (2002), 53(4,5), 269-274
CODEN: IULIF8; ISSN: 1521-6543

PB Taylor & Francis Inc.

DT Journal; General Review

LA English

AB A review with refs. P-glycoprotein (P-GP)-based multidrug resistance (MDR) and undesirable side effects are significant drawbacks to the clin. use of **paclitaxel** and docetaxel. Extensive SAR studies of **taxanes** in these labs. led to the discovery of new generation **taxanes** that are highly active against not only drug-sensitive but also drug-resistant human cancer cell lines as well as tumor xenografts in mice. One of these second generation **taxanes**, SB-T-110131 (IDN5109), exhibited excellent pharmacol. profile in the preclin. studies and has been selected for clin. development (recoded as Bay 59-8862), which is currently in the phase II clin. trials. Bay 59-8862 is orally active with high bioavailability, showing excellent activity against a variety of drug-resistant tumors. "Advanced second generation **taxanes**" show essentially no difference in cytotoxicity against drug-resistant and drug-sensitive cell lines, virtually overcoming MDR. Photoaffinity labeling of P-GP using photoreactive radiolabeled **paclitaxel** analogs has disclosed the **paclitaxel**-binding domain of P-GP. Highly efficient **taxane**-based MDR reversal agents (TRAs) have also been developed, which can recover the cytotoxicity of **paclitaxel** to practically the original level against **paclitaxel**-resistant MDR expressing cancer cells. Highly promising results have emerged from the study of **taxane**-monoclonal antibody (MAb) immunoconjugates, which have been proved to specifically deliver extremely cytotoxic agents to tumor in an animal model.

RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT